KYMR vs. NBIX: Kymera Therapeutics vs. Neurocrine Biosciences Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Neurocrine Biosciences (NBIX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Neurocrine Biosciences (NBIX) has more than two decades of public-market history since May 23, 1996, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Kymera Therapeutics (KYMR) has an aggressive beta of 2.00, indicating higher sensitivity to broad-market moves, while Neurocrine Biosciences (NBIX) is defensive at 0.29 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Neurocrine Biosciences (NBIX) reports 20.42%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) at 18.98% converts revenue to bottom-line profit above its industry’s benchmark range, while Kymera Therapeutics (KYMR) at 0.00% keeps roughly the typical share for its industry.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Neurocrine Biosciences (NBIX) reports 31.98%, ranking against industry peers normally.

Profitability Metrics

Growth

Neurocrine Biosciences (NBIX) at 21.45% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Neurocrine Biosciences (NBIX) reports EPS growth of 41.95%, ranked against its industry; Kymera Therapeutics (KYMR) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

Both Kymera Therapeutics (KYMR) at 0.05 and Neurocrine Biosciences (NBIX) at 0.12 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Kymera Therapeutics (KYMR) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Kymera Therapeutics (KYMR) nor Neurocrine Biosciences (NBIX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Neurocrine Biosciences (NBIX) trades at 24.43 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Neurocrine Biosciences (NBIX) at 4.50 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

Neurocrine Biosciences (NBIX) at 4.30 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics